Levetiracetam Ibigen (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which modulates the release of neurotransmitters. This action stabilizes neuronal membranes, reduces excessive neuronal firing, and lowers the likelihood of seizure propagation without directly blocking sodium or calcium channels.

The appropriate dose of Levetiracetam Ibigen is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

Safety data for levetiracetam during pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is necessary, close monitoring of both mother and infant is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Levetiracetam offers a distinct mechanism of action through SV2A binding, which often results in fewer drug‑drug interactions compared with enzyme‑inducing agents like carbamazepine. It is generally well tolerated, has a rapid onset when given intravenously, and does not require routine serum level monitoring, making it a convenient option for many seizure types.

Levetiracetam Ibigen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light. Do not freeze the product, and ensure that any reconstituted solution is used within the time frame specified by the manufacturer.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and total daily dose are determined by the treating physician according to the patient’s clinical condition and response.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, significant mood alterations like depression or suicidal ideation, hematologic abnormalities (e.g., low platelet counts), and severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these events occur.

Levetiracetam Ibigen is contraindicated in patients with known hypersensitivity to levetiracetam or any of the formulation excipients. Caution is advised in individuals with severe renal impairment, uncontrolled psychiatric disorders, or those who are pregnant or breastfeeding without a clear risk‑benefit assessment.